Excipient-Free Inhalable Microparticles of Azithromycin Produced by Electrospray: A Novel Approach to Direct Pulmonary Delivery of Antibiotics
| Autor: | Maria Pilar Lobera, Jesus Santamaria, Tania Belen Lopez-Mendez, José Luis Pedraz, Beatriz Arauzo, Javier Calzada-Funes |
|---|---|
| Přispěvatelé: | Instituto de Salud Carlos III |
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
Pharmaceutical Science
Excipient Azithromycin Microparticles Article Pharmacy and materia medica medicine Pulmonary administration dry powder Aerosolization azithromycin microparticles COPD Chromatography Lung Inhalation Chemistry Respiratory disease Dry powder pulmonary administration Electrospray medicine.disease Bioavailability RS1-441 medicine.anatomical_structure electrospray medicine.drug |
| Zdroj: | Zaguán. Repositorio Digital de la Universidad de Zaragoza instname Digital.CSIC. Repositorio Institucional del CSIC Addi. Archivo Digital para la Docencia y la Investigación Pharmaceutics; Volume 13; Issue 12; Pages: 1988 Pharmaceutics, Vol 13, Iss 1988, p 1988 (2021) Pharmaceutics |
| Popis: | This article belongs to the Topic Emerging Material-Based Approaches to Chronic and Infectious Diseases. Inhalation therapy offers several advantages in respiratory disease treatment. Azithromycin is a macrolide antibiotic with poor solubility and bioavailability but with a high potential to be used to fight lung infections. The main objective of this study was to generate a new inhalable dry powder azithromycin formulation. To this end, an electrospray was used, yielding a particle size around 2.5 µm, which is considered suitable to achieve total deposition in the respiratory system. The physicochemical properties and morphology of the obtained microparticles were analysed with a battery of characterization techniques. In vitro deposition assays were evaluated after aerosolization of the powder at constant flow rate (100 L/min) and the consideration of the simulation of two different realistic breathing profiles (healthy and chronic obstructive pulmonary disease (COPD) patients) into a next generation impactor (NGI). The formulation was effective in vitro against two types of bacteria, Staphylococcus aureus and Pseudomonas aeruginosa. Finally, the particles were biocompatible, as evidenced by tests on the alveolar cell line (A549) and bronchial cell line (Calu-3). Financial support from Nanbiosis platform, specifically Unit 9 (U9) and Unit 10 (U10) of the Biomedical Research Networking Center in Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN). |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|